# Preserving review context and version control
> Design reviews performed through documents, email, and separate requirements tools can lose context as requirements change during the review cycle. Reviewers may comment on different versions, and consolidating feedback into approved records can be labor-intensive. The central difficulty is preserving which configuration was assessed, what concerns were resolved, and what evidence supported the final approval.
- Status: Current. Last verified 2026-10-15.
- Applies to: Qualitative synthesis of 17 public practitioner discussions, October 2026. Not facts about AskDona, verified audit findings or prevalence statistics.
- Canonical: https://askdona.com/ai/assessment-challenge-14-review-context-version-control.md
14
**Category: CONTROL | Subcategory: Document**
Assessment area: Design Review Assessment
Design reviews performed through documents, email, and separate requirements tools can lose context as requirements change during the review cycle. Reviewers may comment on different versions, and consolidating feedback into approved records can be labor-intensive. The central difficulty is preserving which configuration was assessed, what concerns were resolved, and what evidence supported the final approval.
Design reviews often bring together requirements, risk documents, drawings, test outcomes, and comments from several functions. When the review itself happens in email or word-processing documents while the official requirements are held in a separate system, the assessment context may become fragmented. Changes made during the review can further obscure which revision was actually examined and approved.
Teams may have to manually reconcile comments, re-enter decisions, and determine whether a resolution refers to the current version of a requirement. This increases the chance of duplicated work and incomplete audit trails. Importantly, an electronically recorded approval does not itself establish that the review was technically meaningful; reviewers still need the correct materials and a clearly defined decision to make.
The central challenge is to preserve the identity of the assessed baseline, the substance of the review, and the disposition of comments across tools and revisions so that the resulting approval remains traceable and interpretable.
---
## AskDona Assessment — Preserving Review Context and Version Control
**Topic ID:** 14
**Category:** CONTROL | **Subcategory:** Document
**Assessment area:** Design Review Assessment
**Challenge status:** Current · verified 2026-10-15
**Focus:** Review-baseline identity, controlled revisions, comment disposition, requirements/risk/test traceability, meaningful cross-functional review and reliable approval evidence.
> **Source-integrity note.** Section 1 reproduces the user's challenge verbatim. Quoted excerpts in Sections 2–3 reproduce **the supplied FDA-related analysis**, **not verbatim text from FDA Warning Letters**. That analysis includes both Warning Letters and FDA inspection guidance. **[Outdated — marked 2026-10-16]** Case interpretations have not been independently checked against the linked FDA documents. **Updated (16 Oct 2026):** all 19 linked FDA pages were opened and each Section 2 insight checked; the result is given as a “Fact check” note. References are provided as copyable Markdown links, without inline source citations outside the original excerpts. Regulatory provisions and terminology in historic FDA letters may predate the QMSR effective in February 2026; organizations must determine current, applicable requirements. AskDona prepares evidence-based preliminary assessments for qualified human reviewers and is not itself a validated electronic-signature, electronic design history, or approval system by default.
### 1. Original Challenge — Verbatim
#### 1.1 Title and classification
**Preserving review context and version control**
**Current · verified 2026-10-15 · 14**
**Category: CONTROL | Subcategory: Document**
**Assessment area: Design Review Assessment**
#### 1.2 Original summary
> Design reviews performed through documents, email, and separate requirements tools can lose context as requirements change during the review cycle. Reviewers may comment on different versions, and consolidating feedback into approved records can be labor-intensive. The central difficulty is preserving which configuration was assessed, what concerns were resolved, and what evidence supported the final approval.
#### 1.3 Full original discussion
> Design reviews often bring together requirements, risk documents, drawings, test outcomes, and comments from several functions. When the review itself happens in email or word-processing documents while the official requirements are held in a separate system, the assessment context may become fragmented. Changes made during the review can further obscure which revision was actually examined and approved.
>
> Teams may have to manually reconcile comments, re-enter decisions, and determine whether a resolution refers to the current version of a requirement. This increases the chance of duplicated work and incomplete audit trails. Importantly, an electronically recorded approval does not itself establish that the review was technically meaningful; reviewers still need the correct materials and a clearly defined decision to make.
>
> The central challenge is to preserve the identity of the assessed baseline, the substance of the review, and the disposition of comments across tools and revisions so that the resulting approval remains traceable and interpretable.
#### 1.4 Assessment problem
A defensible review needs more than a signed status: it needs the **exact baseline assessed**, the **applicable criteria**, the **versioned evidence actually considered**, the **open concerns and dispositions**, and the **qualified approval of that particular configuration**. A link to a document title without a revision does not establish this chain.
### 2. FDA Warning Letter–Derived Insights — Original Supplied Analytical Wording
The excerpts below retain the source analysis's wording and numeric reference identifiers. They represent analytical descriptions of FDA materials, not literal FDA Warning Letter quotations.
#### 2.1 Requirement, risk and verification links must remain identifiable
> * **Requirement-to-Risk Gaps:** If a firm updates its procedures to require traceability but fails to provide a clear rationale for why specific requirements are not considered safety risks, or fails to map risk control IDs to specific requirement IDs in a Risk Management Matrix, the integrity of the design is called into question [2].
> * **Specification Disconnects:** Fragmented communication often leads to situations where manufacturing specifications used by contract manufacturers do not correspond to the actual approved changes recorded in Regulatory Assessment Changes (RAC) [10]. This mismatch can lead to unintended dimensional or physical changes in the distributed product [10].
**Fact check (16 Oct 2026, against the linked FDA pages):** **Both partly supported.** Philips [2]: traceability between product requirements and risks was the **firm's own** corrective action; FDA found the “no safety risk” conclusions unjustified, the procedure lacking guidance on what is an appropriate rationale, and the updated Risk Management Matrix not provided. It did not find a failure to map control IDs as such. Medline [10]: manufacturing dimensional specifications used by contract manufacturers did not correspond to the dimensional changes approved in a “Regulatory Assessment of Change” (RAC); FDA says this “may adversely impact product quality”, and “unintended … changes in the distributed product” is the analysis's wording.
#### 2.2 Unapproved or absent controlled records undermine the baseline
> A common deficiency identified in regulatory inspections is the reliance on unapproved, undated, and unsigned design documentation [11, 15]. For example, providing a "Design Plan" at a specific revision level that is undated and lacks approval signatures violates basic Document and Data Control Procedures [15]. Similarly, checklists that reference foundational documents (like a "Product Brief") are useless if those referenced documents cannot be retrieved or do not exist in the official record [15].
> Document control procedures must enforce that all procedures and templates include documented effective dates, evidence of review and approval, and unique document numbers to prevent the active use of outdated or obsolete versions [6, 11].
**Fact check (16 Oct 2026, against the linked FDA pages):** **Vevazz supported; the rest partly.** Vevazz [15]: Design Plan DDP01 Rev 00 is undated and has no signatures as required by the firm's Document and Data Control Procedure; checklists refer to a “Product Brief” that **could not be provided** on request (not that it does not exist). Anigan [11]: procedures had no effective or implementation date and no evidence of review or approval. Effective dates come from Anigan only; Sonesta [6] found procedures without unique document numbers or a required approver signature. “Templates” appears in neither letter, and Sonesta's signature-and-date fix was the firm's commitment.
#### 2.3 Untracked software or firmware versions compromise change history
> When software and firmware changes are introduced during a design or manufacturing cycle, failing to document exactly which revision was deployed at specific serial numbers or batches breaks the chain of version control [16]. Relying on verbal communications to place holds on certain configurations, rather than issuing formal, documented nonconformances, leaves a systematic gap that makes regression failures nearly impossible to track [16].
**Fact check (16 Oct 2026, against the linked FDA pages):** **Mostly supported.** Pensar [16]: firmware/software ECOs took effect at specific serial-number thresholds, no batch record demonstrated implementation of a change, and the hold on ECO 25-033 “was communicated verbally only” with no nonconformance report. The hold was on one ECO; “holds on configurations” is the analysis's generalization.
#### 2.4 Review content, personnel and phase matter
> A technically valid review requires a planned process at appropriate stages of the design project, a detailed description of the information reviewed, and—critically—the active participation of an independent reviewer who does not have direct responsibility for the design stage being evaluated [9]. Reviews that merely document "what needs to be completed next" do not satisfy the requirement for a systematic evaluation of design adequacy and capability [9].
> Without these elements, a signed DHF is technically deficient. It is a critical violation to sign off and approve a DHF when associated design reviews are still marked as "in progress" or lack associated files [17].
**Fact check (16 Oct 2026, against the linked FDA pages):** **Both supported (single cases).** TELEMED [9] (ultrasound): design reviews were not formally planned at appropriate stages, lacked a description of the information reviewed, did not include an independent individual without direct responsibility, and the documented review “mentioned what needed to be completed next”. ZYTO [17]: DHF-00664 was signed as approved in June 2021 while the design review showed “in process” with no associated file or date.
#### 2.5 Approval and data integrity require more than a static export
> A computer-generated, secure, and time-stamped audit trail is vital for reconstructing the course of events surrounding the creation, modification, or deletion of an electronic record [12].
> * **Dynamic Data vs. Static Records:** Teams sometimes attempt to remediate a lack of audit trails by printing physical copies (such as chromatograms or requirements lists) [12]. However, static printouts do not preserve the dynamic format of the original electronic record, which is required to fully interpret the history and context of the data [12].
**Scope caution:** These excerpts include device-design, laboratory-record and other regulated-system examples. Their lessons are useful for review governance, but not every cited requirement applies identically to every design review or software system.
**Fact check (16 Oct 2026, against the linked FDA pages):** **First paragraph partly supported; second contains an invented detail.** International Trading Pharm Lab [12] (drugs) defines an audit trail as a secure, computer-generated, time-stamped electronic record allowing reconstruction of events; “vital” is the analysis's word. Printing all chromatograms was the **firm's** proposed fix, which FDA rejected because “a printout or a static record does not preserve the dynamic record format”. **“Requirements lists” does not appear in the letter.**
### 3. Regulatory Findings and AskDona Assessment Mapping
Each finding includes **(A) FDA-derived original wording**, **(B) Finding**, **(C) AskDona perspective**, **(D) Solution**, **(E) Expected benefit**, and **(F) Capability boundary**.
#### Finding 01 — The review baseline is not uniquely identifiable
**A. Original FDA-derived insight**
> A common deficiency identified in regulatory inspections is the reliance on unapproved, undated, and unsigned design documentation [11, 15]. For example, providing a "Design Plan" at a specific revision level that is undated and lacks approval signatures violates basic Document and Data Control Procedures [15]. Similarly, checklists that reference foundational documents (like a "Product Brief") are useless if those referenced documents cannot be retrieved or do not exist in the official record [15].
**B. Finding.** Reviewers can approve different versions under the same document name, or depend on missing/non-effective source records.
**C. AskDona perspective.** Treat baseline completeness and identity as assessment criteria: review ID, product/configuration, requirements revision, risk-file revision, drawing/software version, test evidence and effective dates.
**D. Proposed solution.** Use an expert-defined baseline manifest and load controlled documents with version/effective-date metadata into the designated RAG repository. Run criterion-based checks for missing revision identifiers, inaccessible referenced files or disagreement between the baseline list and retrieved records; return preliminary labels, explanatory comments, quotations and source-file names. Require the reviewer to confirm the authoritative baseline.
**E. Expected benefit.** Reduced ambiguity over what was reviewed; less document hunting when preparing audit packages.
**F. Boundary.** RAG retrieval, metadata scoping and Excel result exports are documented functions. Immutable baselines, cryptographic snapshots and external repository synchronization are separate implementation/validation requirements, not assumed standard features.
#### Finding 02 — Requirement-to-risk traceability is incomplete
**A. Original FDA-derived insight**
> * **Requirement-to-Risk Gaps:** If a firm updates its procedures to require traceability but fails to provide a clear rationale for why specific requirements are not considered safety risks, or fails to map risk control IDs to specific requirement IDs in a Risk Management Matrix, the integrity of the design is called into question [2].
**B. Finding.** A reviewed requirement may lack an associated risk decision or risk-control ID even though a sign-off is present.
**C. AskDona perspective.** Assess the existence and relevance of documented linkages and exclusions, not only whether documents contain matching keywords.
**D. Proposed solution.** Import criteria for each sampled requirement ID, risk classification, control ID and rationale. Search the current requirements specification, RMF, matrix, review minutes and linked tests; flag missing, ambiguous and conflicting mappings for expert reconciliation.
**E. Expected benefit.** Earlier visibility of broken links and more reviewable risk-related approvals.
**F. Boundary.** Evidence-based comparison is supported; guaranteed cross-system relational traceability and automated exhaustive graph maintenance require custom engineering and validation.
#### Finding 03 — Approved engineering changes and implemented specifications diverge
**A. Original FDA-derived insight**
> * **Specification Disconnects:** Fragmented communication often leads to situations where manufacturing specifications used by contract manufacturers do not correspond to the actual approved changes recorded in Regulatory Assessment Changes (RAC) [10]. This mismatch can lead to unintended dimensional or physical changes in the distributed product [10].
**B. Finding.** The approved review may refer to a different configuration from the one actually implemented or communicated downstream.
**C. AskDona perspective.** Make approved-versus-implemented revision agreement a separately documented criterion.
**D. Proposed solution.** Assess an exported change package—change order, current drawing/specification, implementation record, supplier document, risk review and V&V—with explicit part numbers, revisions and effective dates. Produce evidence-linked discrepancy candidates for design assurance and supplier-quality review.
**E. Expected benefit.** Fewer silent specification inconsistencies and clearer handoffs at design transfer.
**F. Boundary.** AskDona cannot establish physical implementation merely from documents; shop-floor, supplier and PLM/QMS controls remain necessary.
#### Finding 04 — Review comments are detached from the revision they address
**A. Original FDA-derived insight**
> Traceability represents the degree to which a relationship can be established between two or more products of the development process, particularly those with a predecessor-successor or master-subordinate relationship (such as a requirement and its implementing design element) [5].
**B. Finding.** Email comments may be closed against superseded wording, with no evidence of review of the updated requirement.
**C. AskDona perspective.** Treat each comment and disposition as a version-bound review item: comment ID, original revision, issue, action, revised artifact, verification, owner and closure status.
**D. Proposed solution.** Configure an Excel checklist from the controlled comment register; use RAG to check whether each selected closure has supporting evidence in the approved revision. Export unclear or unsubstantiated closures for a reviewer to resolve in the authoritative workflow.
**E. Expected benefit.** Lower manual reconciliation effort and clearer reasons why a concern was closed.
**F. Boundary.** Automated capture of all email threads, real-time comment resolution and write-back to ALM/PLM are integration concepts; they are not established native behavior.
**Fact check (16 Oct 2026, against the linked FDA pages):** **Supported.** FDA's 1995 Glossary of Computer System Software Development Terminology [5] (non-binding reference material for FDA investigators) quotes the IEEE definition: “the degree to which a relationship can be established between two or more products of the development process, especially products having a predecessor-successor or master-subordinate relationship”, with the example of a software component's requirements and design.
#### Finding 05 — Review approvals are administratively complete but technically incomplete
**A. Original FDA-derived insight**
> Without these elements, a signed DHF is technically deficient. It is a critical violation to sign off and approve a DHF when associated design reviews are still marked as "in progress" or lack associated files [17].
**B. Finding.** Signatures can coexist with unresolved action items, missing tests and absent assessment documents.
**C. AskDona perspective.** Separate **approval record present** from **substantive review evidence complete** and **open items appropriately dispositioned**.
**D. Proposed solution.** Assess whether required review inputs, minutes, unresolved findings, design/risk decisions, action owners, V&V evidence and closure approvals are present. Classify missing evidence as **Cannot determine** unless a documented requirement is clearly unmet; route final acceptance to the designated expert.
**E. Expected benefit.** Better review quality and fewer paper-complete but evidence-incomplete packages.
**F. Boundary.** AskDona does not replace approved e-signature systems or authenticate signatures by default.
#### Finding 06 — Independent and cross-functional review participation is not documented
**A. Original FDA-derived insight**
> A technically valid review requires a planned process at appropriate stages of the design project, a detailed description of the information reviewed, and—critically—the active participation of an independent reviewer who does not have direct responsibility for the design stage being evaluated [9]. Reviews that merely document "what needs to be completed next" do not satisfy the requirement for a systematic evaluation of design adequacy and capability [9].
**B. Finding.** A meeting invitation or attendee list does not necessarily show meaningful participation or documented resolution of technical concerns.
**C. AskDona perspective.** Assess recorded reviewer roles, inputs considered, critical objections and decisions against organization-approved procedures.
**D. Proposed solution.** Examine review plans, role matrices, meeting records and action dispositions with configured criteria. Return missing or unclear participation evidence; request human confirmation of actual independence and suitability.
**E. Expected benefit.** More consistent quality of phase-gate evidence and reduced dependence on informal recollection.
**F. Boundary.** The tool cannot infer true independence or technical adequacy from names alone.
#### Finding 07 — Software/hardware configuration history is incomplete
**A. Original FDA-derived insight**
> When software and firmware changes are introduced during a design or manufacturing cycle, failing to document exactly which revision was deployed at specific serial numbers or batches breaks the chain of version control [16]. Relying on verbal communications to place holds on certain configurations, rather than issuing formal, documented nonconformances, leaves a systematic gap that makes regression failures nearly impossible to track [16].
**B. Finding.** Teams cannot reliably reconstruct which version was tested, released or included in the review baseline.
**C. AskDona perspective.** Require version specificity through development, test, release and review records.
**D. Proposed solution.** Compare documented software/build identifiers, drawing revisions, test-report configuration IDs, release records and change justifications as configured evidence checks. Escalate missing links and mismatches.
**E. Expected benefit.** Improved configuration-based review readiness and targeted regression-evidence checks.
**F. Boundary.** Deployment telemetry, serial-number genealogy and automatic change-impact propagation require system integrations; a document assessment alone cannot verify installed software.
#### Finding 08 — Exported records omit dynamic history and audit-trail context
**A. Original FDA-derived insight**
> * **Dynamic Data vs. Static Records:** Teams sometimes attempt to remediate a lack of audit trails by printing physical copies (such as chromatograms or requirements lists) [12]. However, static printouts do not preserve the dynamic format of the original electronic record, which is required to fully interpret the history and context of the data [12].
**B. Finding.** A static PDF or spreadsheet may not show the full change/approval history needed to interpret a regulated electronic record.
**C. AskDona perspective.** Explicitly distinguish available static evidence from missing authoritative change histories; mark unsupported claims as uncertain.
**D. Proposed solution.** Add checks for record-system IDs, controlled history exports, modification dates, reviewer identities and access to relevant audit trails. Flag packages that rely only on static representations when dynamic originals are required by the company's procedures or applicable controls.
**E. Expected benefit.** Fewer false assurances based on attractive but incomplete audit packages.
**F. Boundary.** A citation in AskDona's report is **not** a substitute for a secure, time-stamped, validated Part 11 audit trail. Whether Part 11 applies requires case-specific determination.
#### 3.9 Consolidated design-review control objectives
| Control objective | Evidence-based preliminary check | Final human decision |
|---|---|---|
| Review baseline integrity | Identified approved artifact IDs, revisions, dates, product configuration | Which baseline is authoritative |
| Traceability completeness | Requirement ↔ risk/control ↔ design ↔ V&V links | Are linkages technically sufficient? |
| Comment disposition | Comment linked to its affected revision and documented closure evidence | Has the substantive concern been resolved? |
| Review participation | Roles, recorded inputs and relevant independence evidence | Is the review competent, complete and independent where required? |
| Electronic record integrity | Source-system and audit-trail evidence available | Is record control adequate for applicable requirements? |
| Change/re-review | Evidence that changed versions received required reassessment | Must the review be reopened or approvals repeated? |
### 4. Recommended AskDona Assessment Operating Model
1. **Define the decision and baseline.** The design authority selects the product, stage, reviewed configuration and frozen artifact/revision manifest in a controlled system of record.
2. **Author criteria.** QA/design/regulatory specialists define what evidence makes a review complete, including unresolved comment thresholds and revision-specific V&V expectations.
3. **Assemble controlled evidence.** Ingest authorized snapshots/exports of requirements, drawings, risk files, V&V, minutes, action logs and change records into one appropriately scoped RAG repository. Supply metadata for product, revision and effective date; avoid mixing obsolete and current files.
4. **Run preliminary assessments.** Use Excel-based criterion import, pre-question and metadata scoping, configurable labels, and item-level results containing reason, quotation and source-file name.
5. **Investigate exceptions.** Qualified reviewers check source records, adjudicate contradictions, approve dispositions and initiate re-review when required.
6. **Finalize in the authoritative system.** Preserve the expert's final decision, signatures, original dynamic records, revision baseline and verified comment history in the organization's validated QMS/PLM/ALM/document-control workflow.
7. **Manage revisions.** For changed criteria, clone/version the assessment configuration and archive earlier versions instead of silently rewriting historical evaluation rules. Re-execute checks at defined change gates; automated event-driven synchronization is separately scoped.
**Example output (illustrative, not a live run):**
```text
Item: DR-05 — Every closed critical review comment refers to the approved requirement revision.
Preliminary label: Cannot determine
Reason: The comment log records closure for requirement REQ-104 rev B, but the approved baseline lists rev C; evidence of re-review of rev C was not located in the supplied repository.
Evidence: [Exact source quotation to be populated during assessment]
Source: [Controlled source document and revision]
Human action: Confirm closure applies to rev C or reopen the comment in the authoritative design-review workflow.
```
### 5. Example Criteria for a Design Review Assessment Pilot
The following are **proposed, expert-configurable checks**, not a confirmed out-of-the-box AskDona template or an exhaustive regulatory checklist.
| ID | Assessment criterion | Key evidence | Example trigger for review |
|---|---|---|---|
| DR-01 | The review package identifies product, configuration, phase and unique baseline ID. | Review plan, configuration manifest | No unique baseline |
| DR-02 | Each reviewed requirement names an approved revision and effective date. | Requirements export, approvals | Unknown/obsolete revision |
| DR-03 | Risk-file and risk-control revisions correspond to the assessed design baseline. | RMF, risk matrix, review plan | Baseline mismatch |
| DR-04 | V&V reports identify the design/software configuration tested. | Test report, build record | Test revision not specified |
| DR-05 | Critical comments link to the requirement revision against which they were resolved. | Review comment/action log | Closed against superseded revision |
| DR-06 | Every open significant comment has documented disposition, owner and follow-up gate. | Review minutes, action tracker | Open item silently closed |
| DR-07 | The review record lists required disciplines and appropriate independent reviewer involvement. | SOP, attendee/approval record | Missing role or evidence |
| DR-08 | The review identifies the objective evidence on which major design decisions were based. | Minutes, test/risk reports | Conclusion without linked support |
| DR-09 | An approved design change has been evaluated against current requirements and downstream specifications. | ECO, drawing, supplier document | Revised spec not distributed |
| DR-10 | A change affecting the assessed baseline has a documented re-review or justified no-re-review decision. | Change impact analysis, review history | New revision with old sign-off |
| DR-11 | Records relied on for approval remain accessible in their authoritative, appropriately controlled form. | DMS/QMS/ALM records | Referenced file missing |
| DR-12 | Where applicable, audit-trail and electronic-approval context can be retrieved from the validated system of record. | Electronic history export, access controls | Static printout only |
**Suggested labels:** `Supported`, `Gap`, `Not applicable`, `Cannot determine`—definitions must be set and validated for the particular workflow. Insufficient documentation does not automatically prove that a design is unsafe or noncompliant.
### 6. AskDona Capabilities: Established vs. Proposed
| Capability | Status based on supplied AskDona materials | Safe positioning |
|---|---|---|
| Import assessment criteria from Excel and export results into mapped columns | **Documented existing** | Apply a consistent design-review checklist and produce structured first-pass findings |
| Retrieve relevant text through RAG and return result, reason, quoted evidence and source file | **Documented existing** | Locate evidence and make each preliminary finding reviewable |
| Configure labels including an uncertainty category | **Documented existing/configurable** | Avoid forcing a supported conclusion when evidence is missing |
| Use pre-questions, metadata filters and item filters | **Documented existing** | Scope the assessment to a specific configuration or review context where metadata is well controlled |
| Human expert final review | **Operating principle** | Keep final review and approval in authorized personnel's hands |
| Preserve published assessment history and clone/archive assessment configurations | **Documented platform lifecycle support** | Use controlled assessment versions; do not treat this as an immutable external design baseline |
| Automatically consolidate email/PLM/ALM comments and write back resolutions | **Integration concept; not demonstrated as general release** | Define API/export integration and validate against partner systems |
| Immutable baseline snapshots, qualified e-signatures and full Part 11 audit trails | **Not established as native AskDona capability** | Continue to use validated systems of record |
| Automatic change-impact propagation and selective re-assessment | **Research/roadmap-dependent** | Pilot with controlled inputs; do not promise continuous synchronization |
| Byte-identical repeatability across the entire pipeline | **Demonstrated in a specific research pipeline under tested conditions** | Research feasibility only; not a blanket commercial-production guarantee |
**Important:** Source quotations demonstrate where text was found, not by themselves whether a reviewer considered all relevant evidence or whether a conclusion is correct. The supplied reproducibility research distinguishes stable outputs from accuracy and states that domain-expert validation remains necessary.
### 7. Proposed Pilot and Expected Benefits
#### 7.1 Scope
Pilot on one design-review gate and one recent change package. Select approximately **20–40 sample artifacts/issues**, spanning current and superseded requirements, closed and open comments, risk controls, and relevant V&V results. Define roughly **12 expert-approved criteria** above. Freeze the input corpus for baseline testing and deliberately add cases with missing files, incorrect revisions and inconsistent dispositions.
#### 7.2 Execution
1. Establish gold-standard human assessments and document what counts as a valid revision match.
2. Ingest controlled exports and annotate their product/revision metadata.
3. Run AskDona first-pass assessments; manually verify quotations against the authoritative source.
4. Adjudicate each finding, including false positives, missed inconsistencies and incorrect version matching.
5. Repeat on the same fixed corpus, then on a controlled revised corpus, to measure stability and the ability to explain changed results.
6. Record expert dispositions and approvals in the existing system of record, not solely in the AskDona export.
#### 7.3 Success measures — prospective, not proven outcomes
| KPI | How to measure it | Expected direction |
|---|---|---|
| Baseline-identification completeness | % packages with all required revision IDs | Increase |
| Unsupported comment closures | % sampled closed comments missing current-revision evidence | Decrease |
| Citation validity | % quotations verified in the claimed source/version | Increase |
| Revision-mismatch detection | Precision/recall against expert-labelled mismatches | Increase |
| Evidence retrieval effort | Reviewer minutes locating source records | Decrease |
| Review package preparation | Hours to assemble decision and disposition evidence | Decrease |
| Re-review responsiveness | Time to identify issues affected by a controlled change | Decrease |
| False assurance rate | % inadequately supported items incorrectly labeled supported | Minimize |
The business outcome is **faster assembly of reviewable evidence**, **fewer undetected revision mismatches**, **better continuity of design rationale**, and **more focused specialist review**. These are expected benefits to validate in a pilot, not quantified results demonstrated for this specific use case. Previously reported accuracy or labor savings from security-sector PoCs must not be generalized to design-review work.
### 8. FDA Related URLs — Copyable Markdown Links
These are the complete destinations provided in the supplied FDA-derived analysis. The list contains **Warning Letters and FDA guidance**, which are identified separately. **[Outdated — marked 2026-10-16]** They have not been independently checked here for the precise case statements quoted above. **Updated (16 Oct 2026):** all 19 linked FDA pages were opened and each Section 2 insight checked; the result is given as a “Fact check” note. Firm names, letter numbers and dates match. Of the uncited references, Zimmer Biomet [1] (cited by FDA under design validation), Caltag [3], Circulatory Technology [4] and MiBo [7] concern device design review or design changes; [8], [13], [14] and [19] are drug data-integrity or audit-trail letters, and [18] is a food-industry guide for FDA investigators.
1. [Zimmer Biomet, Inc. — FDA Warning Letter, 2018](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zimmer-biomet-inc-558176-08242018)
2. [Royal Philips — FDA Warning Letter, 2025](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-philips-709948-09092025)
3. [Caltag Medsystems Ltd — FDA Warning Letter, 2023](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/caltag-medsystems-ltd-662115-08312023)
4. [Circulatory Technology, Inc. — FDA Warning Letter, 2019](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/circulatory-technology-inc-572970-01282019)
5. [Glossary of Computer System Software Development Terminology — FDA Inspection Guide](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/glossary-computer-system-software-development-terminology-895)
6. [Sonesta Medical AB — FDA Warning Letter, 2023](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sonesta-medical-ab-667325-09222023)
7. [Mibo Medical Group — FDA Warning Letter, 2018](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mibo-medical-group-558900-11202018)
8. [MMC Healthcare Ltd. — FDA Warning Letter, 2024](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mmc-healthcare-ltd-684644-09242024)
9. [TELEMED — FDA Warning Letter, 2017](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/telemed-540646-11142017)
10. [Medline Industries, LP — FDA Warning Letter, 2024](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medline-industries-lp-677545-03182024)
11. [Anigan, Inc. — FDA Warning Letter, 2018](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/anigan-inc-557163-07252018)
12. [International Trading Pharm Lab Inc — FDA Warning Letter, 2020](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-trading-pharm-lab-inc-598537-04242020)
13. [Lex Inc. — FDA Warning Letter, 2023](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lex-inc-656056-08172023)
14. [Nortec Quimica SA — FDA Warning Letter, 2022](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nortec-quimica-sa-639894-12082022)
15. [Vevazz LLC — FDA Warning Letter, 2019](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vevazz-llc-592118-12262019)
16. [Lion Street Medical, d/b/a Pensar Medical LLC — FDA Warning Letter, 2026](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lion-street-medical-dba-pensar-medical-llc-733015-08212026)
17. [ZYTO Technologies, Inc. — FDA Warning Letter, 2023](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zyto-technologies-inc-652316-06212023)
18. [Computerized Systems in the Food Processing Industry — FDA Inspection Guide](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/computerized-systems-food-processing-industry-0)
19. [Tismor Health and Wellness Pty Limited — FDA Warning Letter, 2019](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tismor-health-and-wellness-pty-limited-588104-12052019)
---
**Positioning statement:** *AskDona Assessment helps teams verify that the design-review decision is supported by a traceable, revision-aware body of evidence. It prepares documented first-pass assessments of baselines, links and comment dispositions so qualified experts can approve the right configuration for the right reasons—without replacing the controlled source systems or the accountability of human reviewers.*